icad (NASDAQ:ICAD) Stock

icad

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Earnings

News

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BPTS

ICAD

LIXT

MASI

MICS

NMTR

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.

The Dow traded up 1.09% to 34,961.65 while the NASDAQ rose 0.91% to 14,374.77. The S&amp;P 500, also rose, gaining, 0.77% to 4,557.83.

Nasdaq Gains Over 100 Points; Lockheed Martin Profit Tops Expectations

Small Cap

Movers

ABOS

ADES

APLS

APVO

ARDS

ATRO

ATUS

AWIN

EOSE

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXPI

FREY

FWBI

GRRR

HCTI

HYPR

INOD

IRNT

ISUN

LINK

MBWM

MNMD

NOVN

PACW

PIRS

QBTS

RVYL

SCHW

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SNAX

UTME

Gainers


	Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.


Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 300 points on Tuesday.

The Dow traded up 1% to 34,932.08 while the NASDAQ rose 0.34% to 14,293.55. The S&amp;P 500, also rose, gaining, 0.46% to 4,543.70.

Dow Jumps Over 300 Points; Morgan Stanley Posts Upbeat Earnings

icad Inc

Icade

<h3>Gainers</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares rose 27.4% to $13.5 during Monday's pre-market session. The market value of their outstanding shares is at $702.3 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares rose 25.08% to $0.35. The market value of their outstanding shares is at $15.5 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares moved upwards by 23.0% to $0.44. The market value of their outstanding shares is at $52.6 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 21.95% to $0.32. The market value of their outstanding shares is at $9.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 15.06% to $0.47. The company's market cap stands at $4.0 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock rose 14.29% to $0.49. The company's market cap stands at $9.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares fell 45.3% to $0.08 during Monday's pre-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares fell 16.29% to $4.01. The company's market cap stands at $232.1 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares decreased by 14.79% to $4.15. The company's market cap stands at $57.2 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 14.38% to $2.74. The market value of their outstanding shares is at $72.2 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock fell 13.17% to $5.87. The market value of their outstanding shares is at $113.4 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) stock fell 12.22% to $4.6. The market value of their outstanding shares is at $173.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ANVS

CUTR

GHRS

HCWB

IVVD

NVCT

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PRPH

VIRX

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

Icad shares are trading higher after the company provided Q4 revenue guidance above estimates.

iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) ("iCAD" or the "Company"), a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported select preliminary, unaudited financial results for the fourth quarter of 2024. Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter of 2024 to be between approximately $5.1 and approximately $5.3 million. Total Annual Recurring Revenue (T-ARR) was approximately $9.8 million, up 11% year-over-year. In the fourth quarter of 2024, the Company closed 106 deals, 19 of which were cloud deals with both new and established customers.

Guidance

ICAD Expects Q4 2024 Revenue Between $5.1M-$5.3M; Total Annual Recurring Revenue Reaches $9.8M, Up 11% YoY; Closed 106 Deals, Including 19 Cloud Deals

iCAD shares are trading higher after the company announced it will present its next-generation AI solutions and a second-read AI partnership with Cascaid Health at the RSNA 2024 Annual Meeting.

<a href="https://www.globenewswire.com/Tracker?data=TwjwrnlfW8Qen5u-zdYndKlr5vcGHoIuWTd0bH48Nh3tPUf8i9YA2cWS9NOEhDzB7CEJy_s4AP5ay5ShFgjuBQ==">iCAD, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5.
Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions.

Biotech

General

iCAD Presents Next-Generation AI Solutions And A Second-Read AI Partnership With Cascaid Health At RSNA 2024

<h3>Gainers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) shares moved upwards by 33.8% to $6.69 during Thursday's pre-market session. The market value of their outstanding shares is at $59.4 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares moved upwards by 18.3% to $0.39. The company's market cap stands at $2.4 million. As per the press release, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 16.98% to $0.39. The company's market cap stands at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 16.23% to $3.58. The company's market cap stands at $126.2 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 13.01% to $1.12. The company's market cap stands at $7.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares increased by 11.96% to $11.88. The company's market cap stands at $670.3 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares fell 52.4% to $5.08 during Thursday's pre-market session. The company's market cap stands at $98.1 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 23.08% to $1.8. The company's market cap stands at $47.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 22.77% to $4.75. The company's market cap stands at $87.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares fell 19.79% to $2.21. The company's market cap stands at $81.3 million. The company's, Q3 earnings came out today. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares decreased by 18.92% to $42.0. The company's market cap stands at $1.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 17.76% to $2.78. The market value of their outstanding shares is at $32.4 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ATXS

CLDI

FBLG

HROW

OPRX

PDSB

TIVC

VERO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Icad shares are trading lower after the company reported worse-than-expected Q3 revenue results.

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. The company reported quarterly sales of $4.217 million which missed the analyst consensus estimate of $4.521 million by 6.72 percent. This is a 3.54 percent increase over sales of $4.073 million the same period last year.

Earnings Beats

Earnings Misses

icad Q3 2024 Adj. EPS $(0.07) Beats $(0.08) Estimate, Sales $4.217M Miss $4.521M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HYZN

IBTA

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect icad to report an earnings per share (EPS) of $-0.08.
Investors in icad are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 2.94% increase in the share price the following trading session.
Here's a look at icad's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>9.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731434735_0.png" alt="eps graph" />
<h3>Tracking icad's Stock Performance</h3>
Shares of icad were trading at $2.11 as of November 11. Over the last 52-week period, shares are up 64.62%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ICAD/earnings">To track all earnings releases for icad visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For icad

<a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240417" title="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240417">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240417</a>

iCAD Announces The FDA 510k Review Panel Has Rated ItsProFound Detection (V4.0) For Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer, Substantially Equivalent On November 8, 2024

Icad shares are trading higher after the company reported better-than-expected Q2 revenue results

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. The company reported quarterly sales of $5.00 million which beat the analyst consensus estimate of $4.42 million by 13.06 percent. This is a 14.75 percent decrease over sales of $5.87 million the same period last year.

icad Q2 2024 GAAP EPS $(0.07), Inline, Sales $5.00M Beat $4.42M Estimate

iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with <a href="https://www.globenewswire.com/Tracker?data=jz_5bbVlVgr_KeIBZzBtwJpyyXmLx0ZWLz2yQEtGonvNiCFICN9K_F30xFyl_wvNzq4DKkqfJ_Ste5g6b3SKYw==">Windson</a>g Radiology Group, one of US Radiology Specialists, Inc.'s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to implement iCAD's ProFound AI Breast Health at Windsong Radiology center locations.

iCAD And Windsong Radiology Ink Strategic Commercial Agreement To Implement AI-Powered Mammography

Events

iCAD to Highlight Research On Potential Of Its AI Algorithm In Breast Cancer Risk Assessment At SIIM 2024

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares moved upwards by 9.3% to $0.46. The market value of their outstanding shares is at $35.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 24.4% to $1.21 during Monday's after-market session. The company's market cap stands at $49.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 14.04% to $0.84. The company's market cap stands at $14.7 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock decreased by 12.99% to $3.62. The company's market cap stands at $2.1 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares decreased by 9.46% to $1.82. The market value of their outstanding shares is at $15.8 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares declined by 8.86% to $0.17. The company's market cap stands at $3.7 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock decreased by 8.59% to $1.81. The company's market cap stands at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

icad

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga